Open access
Oct 2026
Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.
BACKGROUND Neoadjuvant therapy can improve the survival outcomes of patients with borderline resectable pancreatic cancer (BRPC). However, standard neoadjuvant regimens remain lacking. This study evaluated the clinical feasibility of tislelizumab plus gemcitabine and nab-paclitaxel in the neoadjuvant setting for BRPC....
Yong-Gang He, Xue-Hui Peng, Chen-Hao Jiang et al.
· Annals of Surgical Oncology · 0 citations